Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premenstrual Syndrome - Overview
Premenstrual Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Premenstrual Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premenstrual Syndrome - Companies Involved in Therapeutics Development
Asari Pharma AB
MetVital Inc
Pherin Pharmaceuticals Inc
Transdermal Delivery Solutions Corp
Premenstrual Syndrome - Drug Profiles
(estrogen + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anhydrous enol oxaloacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PH-80PMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Antagonize GABAA Receptor for PMDD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Antagonize GABAA Receptor for PMDD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premenstrual Syndrome - Dormant Projects
Premenstrual Syndrome - Product Development Milestones
Featured News & Press Releases
Aug 15, 2019: Last Patient In for landmark PMDD study
Aug 30, 2018: Asari Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm
Jul 09, 2018: Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine
Apr 24, 2018: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
Apr 24, 2018: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
Apr 06, 2018: Asari Pharma announces the start of a clinical Phase IIB study in patients with premenstrual dysphoric disorder
Apr 04, 2018: Asari Pharma starts recruiting patients for Phase IIB clinical trial of Sepranolone, the world’s first treatment specifically targeting PMDD (premenstrual dysphoric disorder), the severest form of PMS
Apr 03, 2017: Asari Pharma Phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint.
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)
Jun 12, 2014: Umecrine Mood reports prelimiry data from exploratory Phase II study in premenstrual dysphoric disorder
Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Premenstrual Syndrome, H2 2019 7
Number of Products under Development by Companies, H2 2019 8
Number of Products by Targets, H2 2019 10
Number of Products by Stage and Targets, H2 2019 11
Number of Products by Mechanism of Actions, H2 2019 12
Number of Products by Stage and Mechanism of Actions, H2 2019 13
Number of Products by Routes of Administration, H2 2019 14
Number of Products by Stage and Routes of Administration, H2 2019 15
Number of Products by Stage and Top 10 Molecule Types, H2 2019 16


List of Tables


Number of Products under Development for Premenstrual Syndrome, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Premenstrual Syndrome - Pipeline by Asarina Pharma AB, H2 2019
Premenstrual Syndrome - Pipeline by MetVital Inc, H2 2019
Premenstrual Syndrome - Pipeline by Pherin Pharmaceuticals Inc, H2 2019
Premenstrual Syndrome - Pipeline by Transdermal Delivery Solutions Corp, H2 2019
Premenstrual Syndrome - Dormant Projects, H2 2019